Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | PDE9A | O76083 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4359029 | 0.90 | CYP3A4 (0.47) | CYP3A4GPR119PDE9ANR3C1TBK1 | |
| SCHEMBL1128987 | 0.89 | CYP3A4 (0.61) | CYP3A4GPR119PDE9ANR3C1SCN9A | |
| SCHEMBL4366577 | 0.88 | CYP3A4 (0.50) | CYP3A4NR3C1CYP2C9NPC1ALDH1A1 | |
| SCHEMBL4358056 | 0.88 | CYP3A4 (0.49) | CYP3A4GPR119PDE9ACYP2C9NPC1 | |
| SCHEMBL4356654 | 0.83 | CYP3A4 (0.51) | CYP3A4GPR119PDE9ACYP2C9 | |
| SCHEMBL4368642 | 0.83 | GPR119 (0.49) | CYP3A4GPR119PDE9ACYP2C9 | |
| SCHEMBL4355613 | 0.81 | CYP3A4 (0.48) | CYP3A4GPR119NR3C1CYP2C9NPC1 | |
| SCHEMBL4355956 | 0.80 | CYP3A4 (0.57) | CYP3A4GPR119PDE9ASCN9ACYP2C9 | |
| SCHEMBL1128319 | 0.79 | CYP3A4 (0.61) | CYP3A4GPR119NR3C1SCN9ATBK1 | |
| SCHEMBL1129023 | 0.78 | CYP3A4 (0.51) | CYP3A4GPR119NR3C1CYP2C9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | CYP3A4 1503/4885GPR119 1/4885PDE9A 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.